Compare Enveric Biosciences Inc (ENVB) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vistra Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Vistra Corp trades at $158.75 (market cap $55.96B). The key difference: Vistra Corp is far larger — about 8364.7× Enveric Biosciences Inc's market cap, and Vistra Corp pays a 0.55% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vistra Corp for 32 Days on average.
| ENVB | VST | |
|---|---|---|
Market Cap | $6.69M | $55.96B |
Volume | 41,141 | 11,969,036 |
Sector | Health | Utilities |
52-Week High | $10.80 | $210.85 |
52-Week Low | $1.27 | $134.71 |
Typical Hold Time | 14 Days | 32 Days |
Enterprise Value | -$1.60M | $77.89B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Vistra Corp. (VST) trades at $166.72, up 3.88% today, with a bullish technical signal and strong analyst support. The stock shows robust profitability with a net income margin of 11.55% and ROE of 75.73%, though earnings have been mixed recently. Recent developments include a $4.2 billion US loan to boost nuclear power and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook is positive given strategic positioning in AI power infrastructure, but risks include earnings volatility and high valuation multiples. The consensus price target of $215.23 implies significant upside, supported by institutional interest and favorable sector trends. Investors should weigh growth prospects against execution risks and market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
